New drug triggers rapid cell death in cancer models
BRD-810 inhibits the MCL1 protein and reactivates apoptosis in tumor cells, displaying therapeutic potential in animal models.

Credit: National Cancer Institute
Human cells with acute myelocytic leukemia (AML) in the pericardial fluid.
Funding
Support for this research was provided in part by the Robertson Foundation and a National Cancer Institute grant 5R35CA242457.
Paper cited
Rauh U, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature Cancer. Online August 23, 2024. DOI: 10.1038/s43018-024-00814-0.